Availability and utilization of cardiovascular fixed-dose combination drugs in the United States

American Heart Journal
Bo WangAaron S Kesselheim

Abstract

Solid clinical evidence supports the effectiveness and safety of multiple drugs in treating diabetes, dyslipidemia, and hypertension, and numerous fixed-dose combination products (FDCs) containing such drugs have been developed for patients with more severe forms of these diseases. We sought to evaluate the extent to which utilization of treatment combinations for these conditions corresponded to the availability of FDCs. Using claims data from a large national commercial insurer, we identified 2 cohorts of patients: those who filled multiple single-agent drugs to treat diabetes, dyslipidemia, and hypertension in 2012, and those who used FDCs containing these products during the same period. We determined the fill rate of single-agent pairs and FDCs, availability of FDCs for the most frequently filled single-agent and drug class pairs, and the number of conditions treated by frequently filled single-agent pairs and FDCs. During our study period, 848,082 patients filled prescriptions for 3,248 unique single-agent pairs (mean 4.7 per patient, standard deviation [SD] 5.0); and 568,923 patients received prescriptions for 43 unique FDCs (mean 1.1 per patient, SD 0.3). Three (15%) of the 20 most frequently filled single-agent pairs w...Continue Reading

References

Jun 28, 2003·BMJ : British Medical Journal·N J Wald, M R Law
Nov 18, 2005·The American Journal of Cardiology·David G Orloff
Nov 23, 2006·Nature Reviews. Drug Discovery·Simon Frantz
Feb 22, 2008·Journal of General Internal Medicine·Feng PanA Mark Fendrick
Oct 29, 2008·Pharmacoepidemiology and Drug Safety·Niteesh K ChoudhryWilliam H Shrank
Aug 12, 2009·Journal of Pain & Palliative Care Pharmacotherapy·UNKNOWN U.S. Food and Drug Administration
Mar 31, 2010·Circulation·Steven Baroletti, Heather Dell'Orfano
May 13, 2010·JAMA : the Journal of the American Medical Association·Harindra C WijeysunderaSimon Capewell
Sep 3, 2013·Diabetes Research and Clinical Practice·Jun-Sing WangUNKNOWN acarbose/metformin fixed-dose combination study investigators
Sep 5, 2013·JAMA : the Journal of the American Medical Association·Simon ThomUNKNOWN UMPIRE Collaborative Group

❮ Previous
Next ❯

Citations

Feb 27, 2016·The Journal of Clinical Hypertension·Kalyani B Sonawane DeshmukhRichard A Hansen
Nov 5, 2016·Expert Opinion on Emerging Drugs·Avivit CahnItamar Raz
Apr 19, 2020·American Journal of Hypertension·Matthew R Weir
Jan 5, 2017·Journal of General Internal Medicine·Julie C LauffenburgerMichael A Fischer
Aug 25, 2018·JAMA : the Journal of the American Medical Association·Chana A SacksJerry Avorn
Jan 30, 2019·Therapeutic Innovation & Regulatory Science·Chikara KikuchiTakao Aoyama
Mar 27, 2021·Scientific Reports·Julien CastioniPedro Marques-Vidal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.